What teduglutide actually is, and the gut it was approved to rebuild

GLP-1 gets all the attention. It has a quieter sibling. The same intestinal cells that release GLP-1 also release GLP-2, and GLP-2 does a different job: it tells the gut lining to maintain and grow itself. Teduglutide is a near-copy of that second signal, built to last longer in the body than the original. It is also one of the few peptides in the wider "gut" conversation that carries a real FDA approval, for a condition most people have never heard of. That combination, a genuine drug for a narrow, serious problem, is exactly why it's worth separating from the supplement shelf it sometimes gets filed next to.

The peptide the gut already makes

Native GLP-2 is a 33-amino-acid peptide released by L-cells in the intestine after a meal. Its role is trophic, which is a plain way of saying it keeps the absorptive lining in good repair and prompts it to grow. Left on its own, it doesn't stay around long. An enzyme called DPP-4 breaks it down within minutes, so the natural signal is a brief one.

Teduglutide changes a single amino acid near one end. That one substitution makes the molecule resistant to DPP-4, so the message survives for hours instead of minutes. The biology it triggers is the body's own: taller intestinal villi, deeper crypts, more surface area for absorbing fluid and nutrients. It is a longer-lasting version of a signal the gut already knows how to read.

The one thing it was approved for

In 2012 the FDA approved teduglutide, sold as Gattex in the United States and Revestive elsewhere, for short bowel syndrome in people who depend on parenteral support. A pediatric clearance, down to age one, followed in 2019.

Short bowel syndrome is not a wellness complaint. It happens when enough of the small intestine is missing, often after surgery, that the remaining gut can't absorb what a person needs to live, and they rely on nutrition delivered through a vein. In its trials, teduglutide helped some patients reduce how much of that intravenous support they needed, by coaxing the intestine they still had to absorb more. That is the whole of what the approval certifies: a specific, severe condition, a defined population, a measured effect on parenteral dependence.

The mechanism is also the warning

Here is the part the enthusiasm tends to skip. The drug works by telling tissue to grow, and tissue growth is not a thing you want to encourage without watching it. The label reflects that. A colonoscopy is recommended before starting and periodically after, because a signal that grows the intestinal lining could also grow polyps or worse. The prescribing information also flags bowel obstruction, gallbladder and pancreatic disease, fluid overload in people with heart conditions, and increased absorption of other oral medications. It carries a formal risk program for prescribers.

None of that makes the biology sinister. It makes it potent, and potent in a direction that requires monitoring. The same property that helps a failing gut recover is the reason the drug lives inside a clinic, not a cabinet.

Why it shows up in the wrong aisle

Teduglutide drifts into "gut peptide" and "gut repair" marketing, often in the same breath as compounds like BPC-157. The grouping is understandable and misleading. One of these is a prescription orphan drug with large trials, a label, and a surveillance requirement. The others mostly circulate as research chemicals with far thinner human files. Calling them all "gut peptides" flattens the one distinction that matters: whether a compound has been studied and cleared for a defined use, or is being borrowed on the strength of its mechanism.

How to hold it

The three questions that work for any peptide work cleanly here. Which signal does it copy, and how was it changed? GLP-2, made durable against DPP-4. Approved for whom, and for what? Short bowel syndrome, in people on parenteral support, nothing wider. And what does the mechanism cost? Enough that growing the gut lining comes with scheduled colonoscopies.

Run those and teduglutide reads as what it is: a well-designed drug with a real, bounded job, and a monitoring plan that exists precisely because it does that job well. The mechanism is elegant. The clearance is narrow on purpose. Keeping the two in separate columns from the general "gut health" pitch is most of what reading it honestly requires.

---

This post is educational and general in nature. It is not medical advice. For guidance about your own health, talk to a qualified clinician.